| Literature DB >> 35465155 |
Silke D Werle1, Nensi Ikonomi1, Julian D Schwab1, Johann M Kraus1, Felix M Weidner1, K Lenhard Rudolph2, Astrid S Pfister3, Rainer Schuler1, Michael Kühl3, Hans A Kestler1.
Abstract
Controlling phenotypical landscapes is of vital interest to modern biology. This task becomes highly demanding because cellular decisions involve complex networks engaging in crosstalk interactions. Previous work on control theory indicates that small sets of compounds can control single phenotypes. However, a dynamic approach is missing to determine the drivers of the whole network dynamics. By analyzing 35 biologically motivated Boolean networks, we developed a method to identify small sets of compounds sufficient to decide on the entire phenotypical landscape. These compounds do not strictly prefer highly related compounds and show a smaller impact on the stability of the attractor landscape. The dynamic driver sets include many intervention targets and cellular reprogramming drivers in human networks. Finally, by using a new comprehensive model of colorectal cancer, we provide a complete workflow on how to implement our approach to shift from in silico to in vitro guided experiments.Entities:
Keywords: Boolean network; Cellular phenotype control; Dynamic driver; Implicants; Intervention targets; Network dynamics
Year: 2022 PMID: 35465155 PMCID: PMC9010550 DOI: 10.1016/j.csbj.2022.03.034
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 6.155
Fig. 1Identification of dynamic drivers. The upper part shows a toy model consisting of three nodes (x1, x2, x3) and corresponding regulatory logic functions. The update scheme is represented as a circuit, and two-time steps are depicted, which are required to determine the entire states of the model based on the predefined driver (here x3). Colors and symbols are explained in the legend. Below is a complete logic workflow of the two implemented approaches to identify dynamic drivers. On the left, in green, is shown the heuristic approach. The exhaustive one is depicted on the right in yellow. Finally, operative examples based on the toy model are displayed on both sides of the flow chart for each approach. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2Dynamic in silico analyses. (A) The dynamic drivers' overall set size is small and independent of the network size (best fit with logarithmic fit). (B) Regulatory interactions of nodes in Boolean network models are comparable to their biological representatives. (C) The majority of dynamic drivers are no hub nodes. Nodes are defined as hubs if their z-score was > 2.5 [24]. Statistics were performed with Cochran’s Q test with a post-hoc pairwise sign test with Bonferroni correction. (D) Distribution of z-transformed connectivity among dynamic drivers, hubs, and other nodes. (E) Percentage of missing attractors or (F) additional attractors after interventions (knockouts/overexpression; Wilcoxon test). We adjust p-values via Bonferroni corrections and assume significant results if p 0.05. p-values are depicted on top of each comparison bar.
Fig. 4Targeting dynamic drivers in vitro. ERK and CIP2A identified as dynamic drivers were targeted individually and in combination. (A) Cell counts from proliferation assay after 24 h post-treatment (n = 5, Wilcoxon test). For both of the single drug treatments, a 2-fold reduction was detected. The combined treatment led to a 3.4-fold decrease. (B) The percentage of dead cells from the proliferation assay shows no significant differences in apoptosis (n = 5, Wilcoxon test). (C, D) The percentage of wound closure after 48 h post-treatment indicates a reduced migratory potential (BVD-523: n = 5, otherwise: n = 6, Wilcoxon test). (E) Merged confocal microscope pictures of E-cadherin staining (green) and colored nuclei (blue) 48 h post-treatment. Treatment of dynamic drivers restored E-cadherin at the cell membrane. We adjust p-values via Bonferroni corrections and assume significant results if p 0.05. p-values are depicted on top of each comparison bar. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Boolean network models investigated Depicted are the described process and the organism for which the model was set up.
| Network | Process | Organism |
|---|---|---|
| Azpeitia et al. | Root stem cell niche | |
| Brandon et al. | Oxidative stress response | |
| Calzone et al. | Cell-fate decision | |
| Cohen et al. | EMT | |
| Dahlhaus et al. | Cancer signaling in neuroblastoma | |
| Davila-Velderrain et al. | Early flower development | |
| Enciso et al. | Lineage fate decision of hematopoietic cells | |
| Fauré et al. | Mammalian cell cycle | |
| García-Gómez et al. | Root apical meristem | |
| Giacomantonio and Goodhill | Cortical area development | |
| Gupta et al. | Neurotransmitter signaling | |
| Herrmann et al. | Cardiac development | |
| Irons | Cell cycle | |
| Klamt et al. | T-cell receptor signaling | |
| Krumsiek et al. | Hematopoiesis | |
| MacLean and Studholme | Type III secretion system | |
| Mai and Liu | Apoptosis | |
| Marques-Pita and Rocha | Body segmentation | |
| Marques-Sanchez et al. | CD4 + T-cell fate | |
| Méndez and Mendoza | B-cell differentiation | |
| Méndez-López et al. | Immortalization of epithelial cells | |
| Mendoza and Xenarios | T-cell signaling | |
| Meyer et al. | Senescence-associated secretory phenotype | |
| Orlando et al. | Cell cycle | |
| Ortiz-Gutiérrez et al. | Cell cycle | |
| Ríos et al. | Gonadal sex determination | |
| Saadatpour et al. | T-cell large granular lymphocyte survival | |
| Sahin et al. | Cell cycle | |
| Sankar et al. | Hormone crosstalk | |
| Siegle et al. | Aging of satellite cells | |
| Sridharan et al. | Oxidative stress | |
| Sun et al. | Endomesoderm tissue specification | |
| Thakar et al. | Immune response | |
| Todd and Helikar | Cell cycle | |
| Yousefi and Dougherty | Metastatic melanoma |
Boolean functions of the Wnt/MAPK network Interactions are described by logical connectives AND (&), OR. (|), and NOT (!). All proteins are abbreviated by the current nomenclature. A detailed biological description of the Boolean functions is provided on GitHub: https://github.com/sysbio-bioinf/DynamicDriverSets.
| Node | Boolean function |
|---|---|
| EGFR | ERBB1/2 & PGE2 &!ERK |
| KRAS | EGFR &!DC |
| RAF | KRAS &!ERK &!AKT |
| MEK | RAF |
| scf | IQGAP1 & RAF & MEK |
| ERK | (scf | PAK1) &!PP2A |
| eIF4F | ERK | mTORC1 |
| EBP1 | !ERK &!mTORC1 |
| MYC | (ERK | TCF/LEF) &!APC & (!PP2A | CIP2A) &!GSK3 |
| cJUN | (ERK | TCF/LEF | COX2) & JNK |
| PI3K | PGE2 | EGFR | KRAS |
| AKT | (PI3K | PAK1 | SNAIL1) &!PP2A & (NF- |
| TSC1/2 | GSK3 |
| mTORC1 | !TSC1/2 |
| S6K | mTORC1 & PI3K |
| TIAM1 | (EGFR | AKT) &!PP2A & (MYC | TCF/LEF) |
| RAC1 | (TIAM1 | IQGAP1 | mTORC1 | PI3K | FZD) &!APC |
| JNK | RAC1 |
| PAK1 | RAC1 &!PP2A |
| IQGAP1 | !GSK3 |
| PGE2 | COX2 | (SNAIL1 & HDAC2) |
| HDAC2 | !APC & MYC |
| ERBB1/2 | HDAC2 | AP1 | TCF/LEF |
| cFOS | (TCF/LEF | ERK) & (ERK | RSK1/2) |
| RSK1/2 | PI3K & ERK |
| AP1 | cFOS & cJUN |
| COX2 | AP1 | NF- |
| FASR | NF- |
| NF- | (RAC1 | ERK | AKT) & HDAC2 & GSK3 |
| CDH1 | (!SNAIL1 &!HDAC2 &!AKT) | (!SNAIL1 & HDAC2 & AKT) | (!SNAIL1 &!HDAC2 & AKT) | (!SNAIL1 & HDAC2 &!AKT) | (SNAIL1 &!HDAC2 &!AKT) | (SNAIL1 & HDAC2 &!AKT) |. (SNAIL1 &!HDAC2 & AKT) |
| Tight junctions | CDH1 & (!IQGAP1 | APC | (RAC1 & IQGAP1)) |
| SNAIL1 | ((AXIN2 | ERK | NF- |
| AXIN2 | TCF/LEF |
| FZD | MEK | ERK | JNK |
| DVL | FZD |
| GSK3 | !PGE2 &!AKT &!ERK &!NF- |
| GSK3 | !APC | GSK3 |
| GSK3 | AXIN1 |
| APC | APC |
| AXIN1 | !DVL |
| DC | !DVL & GSK3 |
| CTNNB1 | !DC |
| TCF/LEF | CTNNB1 & KRAS & RAC1 & (PAK1 | AKT | MEK | IQGAP1 | TIAM1 | NF- |
| PP2A | !CIP2A |
| CIP2A | EGFR | MEK | ERK |
Fig. 3Modeling colorectal cancer progression and intervention. (A) An interaction graph of the colorectal cancer (CRC) model is shown. Dynamic drivers are highlighted in yellow. The size of the circles is proportional to the z-transformed connectivity of the node. (B) Phenotypical distribution during tumor progression is depicted by pie charts. (C) Phenotypical distribution after dynamic driver intervention. In general, phenotypes are assigned based on the activity of nodes responsible for proliferation and migration (see also Appendix Figs. A.2-A.3 and Appendix Method A.4). Please note that simulations were performed considering the opposite behavior of each dynamic driver compared to the adenocarcinoma state (e.g. AKT is active in the adenocarcinoma phenotype, therefore a knockout was performed). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Rationale of selection of dynamic drivers for further laboratory validation Please note that simulations were performed considering the opposite behavior of each dynamic driver compared to the adenocarcinoma state and the activity of cMYC and Tight Junctions nodes.
| Dynamic Driver | Available small molecules | Known for resistance/inefficacy in patients | Target approaches in humans | Targeted in CRC KRAS patients | ||
|---|---|---|---|---|---|---|
| Proliferation | Adhesion | |||||
| AKT | AKT knockout does not change proliferative potential | AKT knockout restores adhesion | NCT 01,333,475 | |||
| APC | APC knock-in inhibits proliferation | APC knock-in restores adhesion | – | – | – | |
| CIP2A | CIP2A knockout inhibits proliferation | CIP2A knockout restores adhesion | – | – | ||
| ERK | ERK knockout inhibits proliferation | ERK knockout restores adhesion | – | – | ||
| GSK3β | GSK3β knock-in inhibits proliferation | GSK3β knock-in restores adhesion | – | – | – | |
| TCF/LEF | TCF/LEF knockout does not change proliferation | TCF/LEF knockout does not affect adhesion | Problems of complex selectivity | Specific inhibition of Wnt will destroy tissue homeostasis | – | – |
| RAC1 | RAC1 knockout inhibits proliferation | RAC1 knockout restores adhesion | Developing selective inhibitors is still an open issue | – | – | – |